PharmaTelevision - Marc Van de Craen of Biotech Subsidy talks about how they help companies discover what European and regional grants are available to them

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Marc Van de Craen of Biotech Subsidy talks about how they help companies discover what European and regional grants are available to them

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Marc Van de Craen, Founding Partner of Biotech Subsidy

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Focus and business

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BioTrinity 2011. On this show I have Marc Van de Craen, who is the Founding Partner of a company called BiotechSubsidy, welcome to the show.

Marc Van de Craen:

Good, thank you for having me.

Fintan Walton:

BiotechSubsidy is a company that'ss based in Belgium and you'sre a company that supports startup companies, small emerging companies and other types of companies to get grants?

Marc Van de Craen:

Yes.

Fintan Walton:

Could you tell us first of all just little bit about how the company was founded, and what'ss your current, what sort of clients you are working with and how you build your business?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Marc Van de Craen

PARTNER

Marc Van de Craen currently serves as Partner at BiotechSubsidy . Next to strategic consulting, Marc Van de Craen has created a partnership ( BiotechSubsidy) focusing on optimizing the subsidy management of biotech SMEs. This partnership was granted over 11 million Euro subsidy in Europe (regional and European subsidies), the US and Asia. Marc Van de Craen earned his Ph.D. in Biotechnology at the University of Ghent in 1998. Next he joined Devgen where he headed after a couple of years different departments for up to 3 line functions with one team based in Singapore. He also acted as a consultant for biotech companies (Ablynx). His specialties include biotechnology, project management, subsidies, pharmaceutical industry, agricultural industry and veterinary industry.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

BiotechSubsidy

BiotechSubsidy represents over 60 years experience in pharma, plantbiotech and veterinary medicines. BiotechSubsidy is headquartered close to Brussels and in close contact with the European Commission. BiotechSubsidy'ss international consultancy team consists mainly of former directors in the biotech industry. The team was granted over 16 million Euro subsidy in Europe, the US and Asia. BiotechSubsidy provides services in English, German and Dutch.